AGIO - Agios Pharmaceuticals Stock Price, News & Analysis

$61.30 1.12 (1.86 %)
(As of 11/23/2017 09:55 AM ET)
Previous Close$60.18
Today's Range$60.26 - $61.48
52-Week Range$39.24 - $72.73
Volume186,400 shs
Average Volume522,769 shs
Market Capitalization$2.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.89

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGIO
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio6.00%
Quick Ratio6.00%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$69.89 million
Price / Sales42.76
Cash FlowN/A
Price / CashN/A
Book Value$9.23 per share
Price / Book6.64

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($6.27)
Net Income$-198,470,000.00
Net Margins-506.39%
Return on Equity-69.64%
Return on Assets-43.12%

Miscellaneous

Employees287
Outstanding Shares48,750,000

Frequently Asked Questions for Agios Pharmaceuticals (NASDAQ:AGIO)

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.78) by $0.19. The biopharmaceutical company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company's quarterly revenue was up 26.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.63) earnings per share. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

12 Wall Street analysts have issued 1-year target prices for Agios Pharmaceuticals' shares. Their predictions range from $57.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $75.70 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • 1. Cann analysts commented, "This dinner and discussion with management, experts, and investors offered an update on AG-120 and an in-depth look at AG-221. Takeaways for AG-221 focused on outcomes and commercial use. AG-221 was found to have remarkable outcomes, especially in light of the difficult-to-treat population in the study. The enthusiasm expressed by Drs." (6/11/2017)
  • 2. Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

  • David P. Schenkein M.D., President, Chief Executive Officer, Director (Age 59)
  • Andrew Hirsch, Chief Financial Officer (Age 46)
  • Scott Biller Ph.D., Chief Scientific Officer (Age 61)
  • Christopher Bowden M.D., Chief Medical Officer (Age 56)
  • Steven L. Hoerter, Chief Commercial Officer (Age 46)
  • Lewis Clayton Cantley Ph.D., Director (Age 68)
  • David Scadden M.D., Director
  • Paul J. Clancy, Independent Director (Age 55)
  • Ian T. Clark, Independent Director (Age 56)
  • Kaye I. Foster-Cheek, Independent Director (Age 57)

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital International Investors (6.44%), Capital Guardian Trust Co. (1.50%), First Trust Advisors LP (1.33%), Alkeon Capital Management LLC (0.94%), Artal Group S.A. (0.92%) and Janus Henderson Group PLC (0.80%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., First Trust Advisors LP, Capital International Ltd. CA, Sectoral Asset Management Inc, Point72 Asset Management L.P., Capital Guardian Trust Co., Capital International Inc. CA and Janus Henderson Group PLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Alkeon Capital Management LLC, Pictet Asset Management Ltd., Crestline Management LP, Fernwood Investment Management LLC, Brown Advisory Inc., Oppenheimer & Co. Inc., Schwab Charles Investment Management Inc. and Belpointe Asset Management LLC. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $61.30.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.93 billion and generates $69.89 million in revenue each year. The biopharmaceutical company earns $-198,470,000.00 in net income (profit) each year or ($6.27) on an earnings per share basis. Agios Pharmaceuticals employs 287 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (AGIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Agios Pharmaceuticals (NASDAQ:AGIO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 11 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $75.70 (23.49% upside)

Consensus Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/19/2017SunTrust Banks, Inc.Set Price TargetBuy$80.00N/AView Rating Details
11/17/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$83.00N/AView Rating Details
11/2/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 -> $66.00N/AView Rating Details
9/18/2017J P Morgan Chase & CoReiterated RatingBuy$76.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$78.00HighView Rating Details
8/10/2017Needham & Company LLCBoost Price TargetBuy -> Buy$54.00 -> $72.00MediumView Rating Details
8/8/2017Canaccord GenuitySet Price TargetBuy$90.00LowView Rating Details
8/2/2017Leerink SwannUpgradeMarket Perform -> Outperform$50.00 -> $80.00HighView Rating Details
8/1/2017Janney Montgomery ScottReiterated RatingHoldHighView Rating Details
6/11/2017CannReiterated RatingBuy$75.00MediumView Rating Details
2/16/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$46.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Agios Pharmaceuticals (NASDAQ:AGIO)

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Earnings History by Quarter for Agios Pharmaceuticals (NASDAQ AGIO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($1.65)N/AView Earnings Details
11/1/2017Q3 2017($1.78)($1.59)$10.85 million$11.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.57)($1.78)$10.68 million$11.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
2017 EPS Consensus Estimate: ($6.91)
2018 EPS Consensus Estimate: ($7.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.86)($1.78)($1.81)
Q2 20173($1.91)($1.48)($1.73)
Q3 20173($1.99)($1.50)($1.76)
Q4 20173($1.69)($1.50)($1.61)
Q1 20181($2.06)($2.06)($2.06)
Q2 20181($2.21)($2.21)($2.21)
Q3 20181($2.37)($2.37)($2.37)
Q4 20181($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Agios Pharmaceuticals (NASDAQ AGIO)

Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 92.64%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ AGIO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$60.88$243,520.00View SEC Filing  
11/1/2017David P SchenkeinCEOSell6,000$63.85$383,100.00View SEC Filing  
11/1/2017Scott BillerInsiderSell2,146$62.69$134,532.74View SEC Filing  
10/17/2017Lewis Clayton Jr. CantleyDirectorSell4,000$71.10$284,400.00View SEC Filing  
10/16/2017Lewis Clayton Jr. CantleyDirectorSell1,000$71.09$71,090.00View SEC Filing  
10/4/2017David P SchenkeinCEOSell80,000$70.14$5,611,200.00View SEC Filing  
10/4/2017Scott BillerInsiderSell10,470$70.00$732,900.00View SEC Filing  
10/2/2017David P SchenkeinCEOSell6,000$66.76$400,560.00View SEC Filing  
10/2/2017Scott BillerInsiderSell2,146$67.23$144,275.58View SEC Filing  
9/18/2017David P SchenkeinCEOSell35,000$67.12$2,349,200.00View SEC Filing  
9/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$65.59$262,360.00View SEC Filing  
9/13/2017Lewis Clayton Jr. CantleyDirectorSell1,000$65.47$65,470.00View SEC Filing  
9/11/2017Scott BillerInsiderSell15,000$65.00$975,000.00View SEC Filing  
9/1/2017David P SchenkeinCEOSell6,000$62.20$373,200.00View SEC Filing  
9/1/2017Scott BillerInsiderSell2,146$61.99$133,030.54View SEC Filing  
8/23/2017Lewis Clayton Jr. CantleyDirectorSell4,000$56.85$227,400.00View SEC Filing  
8/2/2017David P SchenkeinCEOSell27,000$59.95$1,618,650.00View SEC Filing  
8/2/2017Scott BillerInsiderSell23,146$59.60$1,379,501.60View SEC Filing  
7/20/2017Lewis Clayton Jr. CantleyDirectorSell9,000$56.36$507,240.00View SEC Filing  
7/19/2017Lewis Clayton Jr. CantleyDirectorSell3,500$56.14$196,490.00View SEC Filing  
7/7/2017Scott BillerInsiderSell2,146$55.00$118,030.00View SEC Filing  
7/3/2017David P SchenkeinCEOSell3,000$51.18$153,540.00View SEC Filing  
6/21/2017Scott BillerInsiderSell4,292$55.00$236,060.00View SEC Filing  
6/14/2017Lewis Clayton Jr. CantleyDirectorSell2,000$50.87$101,740.00View SEC Filing  
6/7/2017David P SchenkeinCEOSell3,000$50.02$150,060.00View SEC Filing  
5/25/2017Lewis Clayton Jr. CantleyDirectorSell2,036$47.10$95,895.60View SEC Filing  
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.00View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.30View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.64View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.00View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.96View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.00View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.68View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.00View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.00View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.00View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Agios Pharmaceuticals (NASDAQ AGIO)

Source:
DateHeadline
Fighting Cancer One Patient At A TimeFighting Cancer One Patient At A Time
finance.yahoo.com - November 21 at 4:11 PM
Agios Posts New Data on Glioma Candidate from Dose Expansion - NasdaqAgios Posts New Data on Glioma Candidate from Dose Expansion - Nasdaq
www.nasdaq.com - November 20 at 10:07 PM
Biotech Stock Performance Review -- Achillion Pharma, Aduro BioTech, Agios ...Biotech Stock Performance Review -- Achillion Pharma, Aduro BioTech, Agios ...
www.prnewswire.com - November 20 at 5:06 PM
Agios Pharmaceuticals Enters Oversold Territory (AGIO)Agios Pharmaceuticals Enters Oversold Territory (AGIO)
www.nasdaq.com - November 20 at 5:06 PM
Agios Pharmaceuticals, Inc. (AGIO) PT Set at $80.00 by SunTrust Banks, Inc.Agios Pharmaceuticals, Inc. (AGIO) PT Set at $80.00 by SunTrust Banks, Inc.
www.americanbankingnews.com - November 20 at 8:18 AM
Agios Pharma (AGIO) Reports Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) - StreetInsider.comAgios Pharma (AGIO) Reports Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) - StreetInsider.com
www.streetinsider.com - November 19 at 3:36 PM
Agios Pharmas ivosidenib shows treatment effect in early-stage glioma study; shares ahead 3% premarket - Seeking AlphaAgios Pharma's ivosidenib shows treatment effect in early-stage glioma study; shares ahead 3% premarket - Seeking Alpha
seekingalpha.com - November 18 at 5:44 AM
Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 ... - GlobeNewswire (press release)Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 ... - GlobeNewswire (press release)
globenewswire.com - November 18 at 5:44 AM
Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive GliomaAgios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma
finance.yahoo.com - November 18 at 5:44 AM
Agios Pharmaceuticals, Inc. (AGIO) Given a $83.00 Price Target by Oppenheimer Holdings, Inc. AnalystsAgios Pharmaceuticals, Inc. (AGIO) Given a $83.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 17 at 12:22 PM
ETFs with exposure to Agios Pharmaceuticals, Inc. : November 16, 2017ETFs with exposure to Agios Pharmaceuticals, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 3:47 PM
Lewis Clayton Jr. Cantley Sells 4,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) StockLewis Clayton Jr. Cantley Sells 4,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock
www.americanbankingnews.com - November 15 at 8:44 PM
Investors Purchase High Volume of Agios Pharmaceuticals Put Options (AGIO)Investors Purchase High Volume of Agios Pharmaceuticals Put Options (AGIO)
www.americanbankingnews.com - November 12 at 4:04 AM
 Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $16.14 Million Brokerages Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $16.14 Million
www.americanbankingnews.com - November 10 at 11:03 AM
Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017
finance.yahoo.com - November 9 at 4:34 PM
 Analysts Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Earnings of -$1.69 Per Share Analysts Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Earnings of -$1.69 Per Share
www.americanbankingnews.com - November 8 at 3:08 AM
ETFs with exposure to Agios Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to Agios Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:20 PM
Analysts Set Expectations for Agios Pharmaceuticals, Inc.s FY2017 Earnings (AGIO)Analysts Set Expectations for Agios Pharmaceuticals, Inc.'s FY2017 Earnings (AGIO)
www.americanbankingnews.com - November 6 at 8:06 AM
Oppenheimer Holdings Comments on Agios Pharmaceuticals, Inc.s FY2017 Earnings (AGIO)Oppenheimer Holdings Comments on Agios Pharmaceuticals, Inc.'s FY2017 Earnings (AGIO)
www.americanbankingnews.com - November 6 at 8:06 AM
Brokers Offer Predictions for Agios Pharmaceuticals, Inc.s FY2017 Earnings (AGIO)Brokers Offer Predictions for Agios Pharmaceuticals, Inc.'s FY2017 Earnings (AGIO)
www.americanbankingnews.com - November 6 at 8:06 AM
Agios Pharmaceuticals, Inc. (AGIO) Insider Scott Biller Sells 2,146 SharesAgios Pharmaceuticals, Inc. (AGIO) Insider Scott Biller Sells 2,146 Shares
www.americanbankingnews.com - November 3 at 6:30 PM
Agios Pharmaceuticals, Inc. (AGIO) CEO Sells $383,100.00 in StockAgios Pharmaceuticals, Inc. (AGIO) CEO Sells $383,100.00 in Stock
www.americanbankingnews.com - November 3 at 5:42 PM
Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 3:32 PM
Todays Research Reports on Stocks to Watch: Exelixis, Inc. and Agios PharmaceuticalsToday's Research Reports on Stocks to Watch: Exelixis, Inc. and Agios Pharmaceuticals
finance.yahoo.com - November 3 at 9:55 AM
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y - NasdaqAgios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y - Nasdaq
www.nasdaq.com - November 2 at 3:53 PM
Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/YAgios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y
finance.yahoo.com - November 2 at 3:53 PM
BRIEF-Agios reports Q3 revenue $11.4 millionBRIEF-Agios reports Q3 revenue $11.4 million
www.reuters.com - November 1 at 8:57 PM
10-Q: AGIOS PHARMACEUTICALS INC10-Q: AGIOS PHARMACEUTICALS INC
www.marketwatch.com - November 1 at 8:57 PM
Agios Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call SlidesAgios Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 1 at 8:57 PM
Edited Transcript of AGIO earnings conference call or presentation 1-Nov-17 12:00pm GMTEdited Transcript of AGIO earnings conference call or presentation 1-Nov-17 12:00pm GMT
finance.yahoo.com - November 1 at 8:57 PM
Agios Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Agios Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 1 at 3:56 PM
Agios Pharmaceuticals, Inc. to Host Earnings CallAgios Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 1 at 3:56 PM
Agios Reports Third Quarter 2017 Financial ResultsAgios Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 3:56 PM
Agios Pharmaceuticals reports 3Q lossAgios Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 1 at 3:56 PM
Agios (AGIO) Q3 Loss Narrower than Expected, Sales BeatAgios (AGIO) Q3 Loss Narrower than Expected, Sales Beat
finance.yahoo.com - November 1 at 3:56 PM
Agios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual MeetingAgios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting
finance.yahoo.com - November 1 at 3:56 PM
Agios Pharmaceuticals, Inc. (AGIO) Receives Average Rating of "Buy" from AnalystsAgios Pharmaceuticals, Inc. (AGIO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 1 at 1:08 PM
Agios Pharmaceuticals, Inc. (AGIO) Issues  Earnings ResultsAgios Pharmaceuticals, Inc. (AGIO) Issues Earnings Results
www.americanbankingnews.com - November 1 at 12:58 PM
Agios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017Agios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017
finance.yahoo.com - October 31 at 4:46 PM
Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : October 31, 2017Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : October 31, 2017
finance.yahoo.com - October 31 at 4:46 PM
Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : October 30, 2017Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : October 30, 2017
finance.yahoo.com - October 30 at 4:28 PM
Agios Pharmaceuticals (AGIO) Q3 Earnings: Whats in Store? - NasdaqAgios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store? - Nasdaq
www.nasdaq.com - October 27 at 11:01 PM
Agios Pharmaceuticals (AGIO) Q3 Earnings: Whats in Store?Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?
www.zacks.com - October 27 at 5:43 PM
Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?
finance.yahoo.com - October 27 at 5:43 PM
Commit To Purchase Agios Pharmaceuticals At $55, Earn 15.6% Annualized Using Options - NasdaqCommit To Purchase Agios Pharmaceuticals At $55, Earn 15.6% Annualized Using Options - Nasdaq
www.nasdaq.com - October 26 at 3:35 PM
Agios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017 - GlobeNewswire (press release)Agios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017 - GlobeNewswire (press release)
globenewswire.com - October 25 at 4:27 PM
Agios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017Agios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017
finance.yahoo.com - October 25 at 4:27 PM
Agios Pharmaceuticals, Inc. (AGIO) Set to Announce Earnings on WednesdayAgios Pharmaceuticals, Inc. (AGIO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:28 AM
ETFs with exposure to Agios Pharmaceuticals, Inc. : October 23, 2017ETFs with exposure to Agios Pharmaceuticals, Inc. : October 23, 2017
finance.yahoo.com - October 23 at 4:44 PM
$11.36 Million in Sales Expected for Agios Pharmaceuticals, Inc. (AGIO) This Quarter$11.36 Million in Sales Expected for Agios Pharmaceuticals, Inc. (AGIO) This Quarter
www.americanbankingnews.com - October 21 at 9:02 AM

Social Media

Financials

Chart

Agios Pharmaceuticals (NASDAQ AGIO) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.